Controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia "AICLA"


Phase N/A Results

Trial Description

To determine whether aspirin or aspirin + dipyridamole would produce a significant reduction in the subsequent occurrence of fatal and nonfatal cerebral infarction.


Trial Design

Randomized, double-blind, placebo-controlled trial of 604 patients.

Patient Involvement

Patients were randomized into one of three groups: A-aspirin (1 g/day); AD-aspirin (1 g/day) + dipyridamole (225 mg/day); P-placebo. Follow-up period of 3 years.


Type Measure Time Frame Safety Issue
Primary Recurrence of fatal or nonfatal cerebral infarction within 3 years.